House
File
2551
H-8151
Amend
House
File
2551
as
follows:
1
1.
Page
3,
after
line
3
by
inserting:
2
<
g.
The
aggregate
manufacturer-level
direct
and
3
administrative
costs
related
to
marketing
and
advertising
of
4
the
prescription
drug
for
the
immediately
preceding
calendar
5
year.
>
6
2.
Page
7,
after
line
3
by
inserting:
7
<
___.
“Interchangeable
biological
product”
means
the
same
as
8
defined
in
section
155A.3.
>
9
3.
Page
7,
after
line
10
by
inserting:
10
<
___.
“Specialty
drug”
means
the
same
as
defined
in
section
11
510E.1.
>
12
4.
Page
7,
line
13,
after
<
or
>
by
inserting
<
need-based
13
payments
paid
>
14
5.
Page
7,
line
17,
after
<
for
>
by
inserting
<
a
specialty
15
drug
or
>
16
6.
Page
7,
line
19,
after
<
equivalent
>
by
inserting
<
or
an
17
interchangeable
biological
product
>
18
7.
Title
page,
by
striking
lines
1
through
3
and
inserting
19
<
An
Act
relating
to
price
transparency
and
cost-sharing
for
20
prescription
drugs,
and
including
applicability
provisions.
>
21
8.
By
renumbering,
redesignating,
and
correcting
internal
22
references
as
necessary.
23
______________________________
LUNDGREN
of
Dubuque
-1-
HF2551.3748
(2)
88
ko/rn
1/
1
#1.
#2.
#3.
#4.
#5.
#6.
#7.
#8.